Shots:
- Verastem reported the dosing of the first patient (US) for P-I/IIa study (VS-7375-101) assessing the safety, tolerability, and efficacy of VS-7375
- The dose-escalation phase of the study starts at 400mg, based on results from a P-I/II study conducted by GenFleet in China, and presented initial safety and efficacy data at ASCO’25
- Upon reaching the RP2D, Verastem will launch expansion cohorts in advanced pancreatic cancer & NSCLC, and along with monotx. Verastem will evaluate VS-7375 in combination with cetuximab in advanced solid tumors, and also expects to initiate a combination expansion cohort in colorectal cancer
Ref: Businesswire| Image: Verastem Oncology | Press Release
Related News:- FDA Grants Verastem Oncology’s Avmapki + Fakzynja Accelerated Approval for KRAS-Mutated Low-Grade Serous Ovarian Cancer (LGSOC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
